Early steroid withdrawal in pediatric renal transplant on newer immunosuppressive drugs

被引:42
作者
Delucchi, Angela
Valenzuela, Marcela
Ferrario, Mario
Lillo, Ana Maria
Guerrero, J. Luis
Rodriguez, Eugenio
Cano, Francisco
Cavada, Gabriel
Godoy, Jorge
Rodriguez, Jorge
Gonzalez, C. Gloria
Buckel, Erwin
Contreras, Luis
机构
[1] Calvo Mackenna Hosp, Santiago, Chile
[2] Univ Chile, Dept Biostat, Santiago, Chile
[3] Univ Chile, Dept Pathol, Santiago, Chile
关键词
immunosuppressive treatment; steroid withdrawal; pediatric kidney transplantation;
D O I
10.1111/j.1399-3046.2007.00735.x
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Steroids have been a cornerstone in renal transplant immunosuppression. New immunosuppressive drugs have led to protocols using early steroid withdrawal or complete avoidance. A prospective protocol in 23 pediatric renal transplant (ages 2-14 yr) who received decreasing steroid doses stopping at day 7 post-Tx, FK, and MMF were compared with a CsA, AZT, historically matched steroid-based control group. Basiliximab was used in two doses. Anthropometric, biochemical variables, AR rates, and CMV infection were evaluated and compared using Student's t-test and regression analysis. A better growth pattern was seen in steroid withdrawal group. GFR rate and serum glucose were similar in both groups. Total serum cholesterol levels were significantly lower in steroid withdrawal group. The incidence of AR at 12 months was 4.3% in steroid withdrawal group vs. 8.6% in steroid-based group (p = ns). No difference in CMV infection was observed. Hemoglobin levels were low during the first months in both groups; reached normal values after six months. SBP became higher at 12 months in steroid-based group. Patient and graft survival was 98% in both groups at one-yr post-transplant. Early steroid withdrawal was efficacious, safe, and did not increase risk of rejection, preserving optimal growth, renal function, and reducing cardiovascular risk factors.
引用
收藏
页码:743 / 748
页数:6
相关论文
共 30 条
[1]  
Ahsan N, 1999, TRANSPLANTATION, V68, P1865
[2]   Cardiovascular risk profile after conversion from cyclosporine A to tacrolimus in stable renal transplant recipients [J].
Baid-Agrawal, S ;
Delmonico, FL ;
Tolkoff-Rubin, NE ;
Farrell, M ;
Williams, WW ;
Shih, V ;
Auchincloss, H ;
Cosimi, AB ;
Pascual, M .
TRANSPLANTATION, 2004, 77 (08) :1199-1202
[3]   Quantitative pp65 antigenemia in the diagnosis of cytomegalovirus disease:: prospective assessment in a cohort of solid organ transplant recipients [J].
Bernabeu-Wittel, M ;
Pachon-Ibáñez, J ;
Cisneros, JM ;
Cañas, E ;
Sánchez, M ;
Gómez, MA ;
Gentil, MA ;
Pachón, J .
JOURNAL OF INFECTION, 2005, 51 (03) :188-194
[4]   GROWTH-RATE IN CHILDREN RECEIVING ALTERNATE-DAY CORTICOSTEROID TREATMENT AFTER KIDNEY-TRANSPLANTATION [J].
BROYER, M ;
GUEST, G ;
GAGNADOUX, MF .
JOURNAL OF PEDIATRICS, 1992, 120 (05) :721-725
[5]   Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation [J].
Cattaneo, D ;
Perico, N ;
Gaspari, F ;
Gotti, E ;
Remuzzi, G .
KIDNEY INTERNATIONAL, 2002, 62 (03) :1060-1067
[6]   A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. [J].
Cole, E ;
Landsberg, D ;
Russell, D ;
Zaltzman, J ;
Kiberd, B ;
Caravaggio, C ;
Vasquez, AR ;
Halloran, P .
TRANSPLANTATION, 2001, 72 (05) :845-850
[7]   Pediatric renal transplantation: A single center experience over 14 years [J].
Delucchi, A ;
Ferrario, M ;
Varela, M ;
Cano, F ;
Rodriguez, E ;
Guerrero, JL ;
Lillo, AM ;
Wolff, E ;
Godoy, J ;
Buckel, E ;
Gonzalez, G ;
Rodriguez, J ;
Cavada, G .
PEDIATRIC TRANSPLANTATION, 2006, 10 (02) :193-197
[8]  
GERNA G, 2006, HERPES, V13, P1
[9]  
HRICIK DE, 1993, J AM SOC NEPHROL, V4, P1300
[10]  
IROBERTI I, 1994, CLIN TRANSPLANT, V8, P405